UroGen Pharma to Present at Upcoming Investor Conferences
31 8월 2023 - 9:00PM
Business Wire
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing novel solutions that treat
urothelial and specialty cancers, today announced that it will
present at the following investor conferences in September:
H.C. Wainwright 25th Annual Global Investment Conference —
September 11-13, 2023
- Presentation: Tuesday, September 12th at 10:00 AM ET
- Webcast Link:
https://journey.ct.events/view/b77088e1-4859-49a5-bdbe-353a3774b1ba
2023 Cantor Fitzgerald Global Healthcare Conference —
September 26 - 28, 2023
- Fireside Chat: Tuesday, September 26th at 8:35 AM ET
- Webcast Link:
https://wsw.com/webcast/cantor19/urgn/2115036
Webcasts for both conferences will be available via the
Investors section of UroGen’s website, www.urogen.com. A replay of
each webcast will be available on the Company’s website for
approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. JELMYTO®
(mitomycin) for pyelocalyceal solution and investigational
treatment UGN-102 (mitomycin) for intravesical solution for
patients with low-grade non-muscle invasive bladder cancer are
designed to ablate tumors by non-surgical means. UroGen is
headquartered in Princeton, NJ with operations in Israel. Visit
www.urogen.com to learn more or follow us on Twitter,
@UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230831174677/en/
INVESTOR CONTACT: Vincent Perrone Senior Director, Investor
Relations vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA CONTACT: Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
UroGen Pharma (NASDAQ:URGN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024